No connection

Search Results

BBNX vs EHAB

BBNX
Beta Bionics, Inc.
BEARISH
Price
$15.96
Market Cap
$702.6M
Sector
Healthcare
AI Confidence
78%
EHAB
Enhabit, Inc.
BEARISH
Price
$13.74
Market Cap
$703.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BBNX
--
EHAB
--
Forward P/E
BBNX
-9.72
EHAB
22.12
P/B Ratio
BBNX
2.38
EHAB
1.31
P/S Ratio
BBNX
7.93
EHAB
0.66
EV/EBITDA
BBNX
-7.15
EHAB
13.71

Profitability

Gross Margin
BBNX
54.51%
EHAB
49.04%
Operating Margin
BBNX
-62.54%
EHAB
5.33%
Profit Margin
BBNX
-87.89%
EHAB
-0.43%
ROE
BBNX
-47.52%
EHAB
-0.46%
ROA
BBNX
-20.08%
EHAB
3.33%

Growth

Revenue Growth
BBNX
63.1%
EHAB
4.7%
Earnings Growth
BBNX
--
EHAB
--

Financial Health

Debt/Equity
BBNX
0.03
EHAB
0.89
Current Ratio
BBNX
10.64
EHAB
1.63
Quick Ratio
BBNX
9.57
EHAB
1.49

Dividends

Dividend Yield
BBNX
--
EHAB
--
Payout Ratio
BBNX
0.0%
EHAB
0.0%

AI Verdict

BBNX BEARISH

BBNX exhibits a critically weak Piotroski F-Score of 1/9, indicating severe financial distress, and lacks an Altman Z-Score, preventing a full solvency assessment. Despite strong revenue growth of 63.1% YoY and a robust gross margin of 54.51%, the company is deeply unprofitable with negative operating and net margins, deteriorating earnings, and a negative Forward P/E of -9.72. Insider selling worth $1.32M over the past six months and a bearish technical trend of 0/100 further signal lack of confidence. While analysts maintain a strong_buy consensus with a $31.80 target price, the current fundamentals and cash flow opacity suggest substantial risk.

Strengths
Exceptional year-over-year revenue growth of 63.10%, significantly above sector average of 38.87%
High gross margin of 54.51%, indicating strong pricing power or cost control in core operations
Exceptionally strong liquidity position with a current ratio of 10.64 and quick ratio of 9.57
Risks
Critically low Piotroski F-Score of 1/9, signaling severe financial weakness and high risk of continued underperformance
Deeply negative profitability: -87.89% profit margin and -47.52% ROE indicate ongoing losses and poor capital efficiency
Negative Forward P/E of -9.72 reflects unprofitability and uncertainty in future earnings trajectory
EHAB BEARISH

EHAB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the stock has seen a significant 1-year price surge (+78.4%), this momentum is disconnected from core profitability, as evidenced by a negative profit margin (-0.43%) and negative ROE (-0.46%). The lack of a Graham Number and the absence of an Altman Z-Score, combined with bearish insider selling, suggest a speculative valuation. The recent price action likely reflects merger speculation mentioned in SEC filings rather than organic growth.

Strengths
Strong 1-year price momentum (+78.4%)
Low Price-to-Sales ratio (0.66)
Healthy liquidity ratios (Current Ratio 1.63, Quick Ratio 1.49)
Risks
Critical financial health failure (Piotroski F-Score 2/9)
Negative net profit margins and negative Return on Equity
Stagnant revenue growth (4.70% YoY)

Compare Another Pair

BBNX vs EHAB: Head-to-Head Comparison

This page compares Beta Bionics, Inc. (BBNX) and Enhabit, Inc. (EHAB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile